Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    Rituximab in Progressive IgA Nephropathy
Previous Study | Return to List | Next Study

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

This study has been completed.
Sponsor:
Collaborators:
Ohio State University
Stanford University
University of North Carolina, Chapel Hill
Columbia University
Genentech, Inc.
Biogen
Information provided by (Responsible Party):
Fernando Fervenza, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00498368
First received: July 9, 2007
Last updated: September 28, 2016
Last verified: September 2016
Results First Received: September 28, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: IgA Nephropathy
Interventions: Drug: Intravenous Rituximab
Drug: ACE/ARB
Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Rituximab Plus ACE/ARB

Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement

Intravenous Rituximab: Rituximab Therapy [27 Patients]

  • Rituximab 1 gm IV on Treatment Day 1
  • Rituximab 1 gm IV on Treatment Day 15
  • Rituximab 1 gm IV on Treatment Day 168
  • Rituximab 1 gm IV on Treatment Day 182
  • An angiotensin converting enzyme (ACE) inhibitors and /or angiotensin II receptor blockers (ARBs) will be used to achieve a B/P goal of <130/80 millimeters of mercury

Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day

ACE/ARB

ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement

ACE/ARB: ACE inhibitors and /or ARBs will be used to achieve a B/P goal of <130/80 millimeters of mercury (mmHg)

Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day


Participant Flow:   Overall Study
    Rituximab Plus ACE/ARB   ACE/ARB
STARTED   17   17 
COMPLETED   14   15 
NOT COMPLETED   3   2 
Withdrawal by Subject                3                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Rituximab Plus ACE/ARB

Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement

Intravenous Rituximab: Rituximab Therapy [27 Patients]

  • Rituximab 1 gm IV on Treatment Day 1
  • Rituximab 1 gm IV on Treatment Day 15
  • Rituximab 1 gm IV on Treatment Day 168
  • Rituximab 1 gm IV on Treatment Day 182
  • An ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of <130/80 millimeters of mercury (mmHg)

Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day

ACE/ARB

ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement

ACE/ARB: ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of <130/80 millimeters of mercury (mmHg)

Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day

Total Total of all reporting groups

Baseline Measures
   Rituximab Plus ACE/ARB   ACE/ARB   Total 
Overall Participants Analyzed 
[Units: Participants]
 17   17   34 
Age 
[Units: Years]
Median (Full Range)
 43 
 (29 to 63) 
 33 
 (21 to 59) 
 40 
 (21 to 63) 
Gender 
[Units: Participants]
     
Female   7   2   9 
Male   10   15   25 
Region of Enrollment 
[Units: Participants]
     
United States   17   17   34 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Proteinuria at 12 Months   [ Time Frame: 1 year ]

2.  Secondary:   Biochemical Marker IgA at 12 Months   [ Time Frame: 12 months ]

3.  Secondary:   Biochemical Marker Gd-Immunoglobulin A Subclass 1 (IgA1) at 12 Months   [ Time Frame: 12 months ]

4.  Secondary:   Biochemical Marker Immunoglobulin G (IgG) AutoAb at 12 Months   [ Time Frame: 12 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Fernando Fervenza
Organization: Mayo Clinic
phone: 507-255-3712
e-mail: Fervenza.Fernando@mayo.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Fernando Fervenza, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00498368     History of Changes
Other Study ID Numbers: 07-001944
Study First Received: July 9, 2007
Results First Received: September 28, 2016
Last Updated: September 28, 2016
Health Authority: United States: Food and Drug Administration